JP2023531722A5 - - Google Patents

Info

Publication number
JP2023531722A5
JP2023531722A5 JP2022579956A JP2022579956A JP2023531722A5 JP 2023531722 A5 JP2023531722 A5 JP 2023531722A5 JP 2022579956 A JP2022579956 A JP 2022579956A JP 2022579956 A JP2022579956 A JP 2022579956A JP 2023531722 A5 JP2023531722 A5 JP 2023531722A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antibody molecule
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022579956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531722A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/038924 external-priority patent/WO2021262999A1/en
Publication of JP2023531722A publication Critical patent/JP2023531722A/ja
Publication of JP2023531722A5 publication Critical patent/JP2023531722A5/ja
Pending legal-status Critical Current

Links

JP2022579956A 2020-06-24 2021-06-24 Aprilに対する抗体分子およびその使用 Pending JP2023531722A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063043558P 2020-06-24 2020-06-24
US63/043,558 2020-06-24
US202063091002P 2020-10-13 2020-10-13
US63/091,002 2020-10-13
US202163136950P 2021-01-13 2021-01-13
US63/136,950 2021-01-13
US202163195527P 2021-06-01 2021-06-01
US63/195,527 2021-06-01
PCT/US2021/038924 WO2021262999A1 (en) 2020-06-24 2021-06-24 Antibody molecules to april and uses thereof

Publications (2)

Publication Number Publication Date
JP2023531722A JP2023531722A (ja) 2023-07-25
JP2023531722A5 true JP2023531722A5 (cg-RX-API-DMAC7.html) 2024-06-24

Family

ID=77022225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579956A Pending JP2023531722A (ja) 2020-06-24 2021-06-24 Aprilに対する抗体分子およびその使用

Country Status (11)

Country Link
US (1) US20260116988A1 (cg-RX-API-DMAC7.html)
EP (1) EP4172206A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023531722A (cg-RX-API-DMAC7.html)
KR (1) KR20230042273A (cg-RX-API-DMAC7.html)
AU (1) AU2021297315A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026639A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187823A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022016591A (cg-RX-API-DMAC7.html)
PH (1) PH12023550198A1 (cg-RX-API-DMAC7.html)
TW (1) TW202216195A (cg-RX-API-DMAC7.html)
WO (1) WO2021262999A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170145086A1 (en) 2015-11-25 2017-05-25 Visterra, Inc. Antibody molecules to april and uses thereof
AU2023262513A1 (en) * 2022-04-25 2024-12-05 Visterra, Inc. Antibody molecules to april and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US20170145086A1 (en) * 2015-11-25 2017-05-25 Visterra, Inc. Antibody molecules to april and uses thereof
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof

Similar Documents

Publication Publication Date Title
TWI859164B (zh) 利用抗fcrn抗體治療葛瑞夫茲氏眼病之方法
Wallach et al. Advances in the treatment of neuromyelitis optica spectrum disorder
JP2023548858A5 (cg-RX-API-DMAC7.html)
EP3487881B1 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
Van Doorn Treatment of Guillain‐Barré syndrome and CIDP
JP2022515770A5 (cg-RX-API-DMAC7.html)
Prasad et al. Intravenous immunoglobulin in pediatrics: A review
JP2025514142A5 (cg-RX-API-DMAC7.html)
US20230049011A1 (en) Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
KR20240117655A (ko) 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임
WO2019020069A1 (zh) 一种sost抗体药物组合物及其用途
JP2019519584A5 (cg-RX-API-DMAC7.html)
WO2022090169A1 (en) Method of safe administration of anti-tau antibody
US12358977B2 (en) Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the IL-20R
CA2946929A1 (en) Treatment and prevention of alzheimer's disease (ad)
Lozano-Blasco et al. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG
Ponleitner et al. Treatment of neuromyelitis optica spectrum disorder: revisiting the complement system and other aspects of pathogenesis
JP2021147383A (ja) アトピー性皮膚炎及び関連障害を処置するための方法
US20240409631A1 (en) Aqueous formulations of an anti-cd22 antibody and uses thereof
WO2020108621A1 (zh) 一种cd40抗体药物组合物及其用途
JP2024522620A5 (cg-RX-API-DMAC7.html)
JP2023534576A5 (cg-RX-API-DMAC7.html)
Ramesh et al. Therapeutic uses of intravenous immunoglobulin (IVIG) in children
TW202114734A (zh) Il-17拮抗劑治療自身免疫疾病的方法
Dhandha et al. Treatment of selective antibody deficiency with IVIG resulting in decreased frequency of streptococcal infection and improvement of guttate psoriasis